Study participants were randomized to conventional enteric-coated aspirin
at 325 mg/day or to the investigational tablet, known for now as PA32540.
Some evidence suggests that using enteric-coated aspirin
may reduce the risk of ulcers and gastric bleeding.
The ADA recommends daily enteric-coated aspirin
for diabetic patients who already have evidence of cardiovascular disease and for those without CVD who have one or more risk factors for the disease, Ms.
(ECASA) is another very safe and much cheaper alternative to acetaminophen and much less expensive than the NSAIDs or the non-acetyl salicylates.
When enteric-coated aspirin
is involved, proper absorption may be delayed and the level of overdosage may not be apparent.
Subjects were randomly assigned to once-daily treatment with PA32540 or 325 mg of enteric-coated aspirin
Measurements indicating the presence of what has been thought to be aspirin resistance were evident only with enteric-coated aspirin
, not immediate-release aspirin, in a study of 400 healthy adults--a phenomenon the study's authors described as aspirin "pseudoresistance.
Joseph brand, which is more than 90 years old, now markets low dose and regular strength enteric-coated aspirin
, as well as Cough and Cold products.
After a few weeks or months, when flushing dissipates, changing to a low-dose (81-mg) enteric-coated aspirin
can minimize stomach upset and the long-term risk of stomach ulcers and bleeding.
Some medications which have been reported to cause pharmacobezoars are aluminum hydroxide gel for treating hyperphosphatemia in renal failure, (6,7,8) enteric-coated aspirin
, (9,10) sucralfate, (11) guar gum, (12) cholestyramine, (13) enteral feeding solution, (13) bulk laxative, (14) and nifedipine XL.
What about using buffered or enteric-coated aspirin
to avoid gastric irritation?
Each study achieved its individual primary endpoint, as patients on PA32540 experienced fewer gastric ulcers compared to those taking enteric-coated aspirin
(325 mg) alone.
Many patients taking daily low-dose enteric-coated aspirin
to prevent cardiovascular events show incomplete platelet inhibition, reported Andrew O.
NASDAQ: POZN),a pharmaceutical company committed to transforming medicine that transforms lives, presented positive results from two pivotal Phase 3 clinical trials of the investigational product, PA32540, at The American Heart Association (AHA) Scientific Sessions 2012, as Poster #12057: Treatment Continuation and Cardiovascular Safety of Antiplatelet Therapy with PA32540, A Tablet with Enteric-Coated Aspirin
and Immediate-Release Omeprazole: Results of Two 6-Month, Phase 3 Studies.
Clinical trials are currently underway to compare the efficacy of Fasprin with that of enteric-coated aspirin
and determine how quickly the dosage reaches the blood stream.